troglitazone has been researched along with Angiitis in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Verrier, E | 1 |
Wang, L | 1 |
Wadham, C | 1 |
Albanese, N | 1 |
Hahn, C | 1 |
Gamble, JR | 1 |
Chatterjee, VK | 1 |
Vadas, MA | 1 |
Xia, P | 1 |
Pasceri, V | 1 |
Wu, HD | 1 |
Willerson, JT | 1 |
Yeh, ET | 1 |
2 other studies available for troglitazone and Angiitis
Article | Year |
---|---|
PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.
Topics: Animals; Aorta; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Chromans; Diabetic | 2004 |
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.
Topics: Animals; Arteriosclerosis; Cell Movement; Cells, Cultured; Chromans; Endothelium, Vascular; Humans; | 2000 |